BioCentury | Jan 29, 2020
Company News

Management tracks: Century Therapeutics, Passage, Forbion, Bavarian, Disc, Biocartis, QuantuMDx and more

...Hepcidin”). Ewoud Welten will resign at the end of March as CFO of Belgian company Biocartis Group N.V....
...chairman. Adams is co-founder and executive chairman of NextWaveBio. BioCentury Staff Century Therapeutics LLC Passage Bio Inc. Bavarian Nordic A/S Biocartis Group N.V. Forbion...
BioCentury | Jan 12, 2019
Finance

JPM jump-starts 2019

...NASDAQ:UROV) 20% $8.29 Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) 20% $21.08 Seattle Genetics Inc. (NASDAQ:SGEN) 20% $71.41 Biocartis Group N.V....
BioCentury | Dec 21, 2018
Financial News

New Rhein raises $47.7M towards debut fund

...partners Subhanu Saxena and Ivan Gergel, who is also CMO. Parekh previously was CEO of Biocartis Group N.V....
BioCentury | Dec 20, 2018
Financial News

New Rhein raises $47.7M towards debut fund

...partners Subhanu Saxena and Ivan Gergel, who is also CMO. Parekh previously was CEO of Biocartis Group N.V....
BioCentury | Nov 17, 2018
Emerging Company Profile

Sepset’s sepsis signature

...The company signed a deal with Biocartis Group N.V. in January to transfer its sepsis assay to Biocartis’...
BioCentury | May 11, 2018
Company News

Merck, J&J vaccines ready for Ebola outbreak

...glycoprotein and MVA-BN Filo is a modified vaccinia Ankara (MVA) multivalent vaccine. J&J and partner Biocartis Group N.V....
...uses the Biocartis Idylla real-time, reverse transcription-PCR system to detect the virus within 100 minutes. Biocartis...
BioCentury | May 9, 2018
Politics & Policy

Merck, J&J vaccines ready for Ebola outbreak

...glycoprotein and MVA-BN Filo is a modified vaccinia Ankara (MVA) multivalent vaccine. J&J and partner Biocartis Group N.V....
...uses the Biocartis Idylla real-time, reverse transcription-PCR system to detect the virus within 100 minutes. Biocartis...
BioCentury | Feb 22, 2018
Finance

Belgian Insights

...Edwin Moses, Ph.D., CEO, Ablynx N.V. Rudi Pauwels, Ph.D., Founder and Chairman of Strategy Committee, Biocartis Group N.V....
BioCentury | Dec 1, 2017
Financial News

Biocartis raises EUR80M in private placement

...On Nov. 28, diagnostic company Biocartis Group N.V. (Euronext:BCART) raised €80 million ($94.4 million) through the sale of...
...for infectious diseases and oncology based on its Idylla platform. Biocartis Group N.V. (Euronext:BCART), Mechelen, Belgium Elizabeth S. Eaton Biocartis Group N.V....
BioCentury | Nov 29, 2017
Financial News

Biocartis raises €80M in private placement

...Diagnostic company Biocartis Group N.V. (Euronext:BCART) raised €80 million ($94.4 million) through the sale of 6.4 million new...
...menu of diagnostic tests for infectious diseases and oncology based on its Idylla platform. Elizabeth S. Eaton Idylla Biocartis Group N.V....
Items per page:
1 - 10 of 80
BioCentury | Jan 29, 2020
Company News

Management tracks: Century Therapeutics, Passage, Forbion, Bavarian, Disc, Biocartis, QuantuMDx and more

...Hepcidin”). Ewoud Welten will resign at the end of March as CFO of Belgian company Biocartis Group N.V....
...chairman. Adams is co-founder and executive chairman of NextWaveBio. BioCentury Staff Century Therapeutics LLC Passage Bio Inc. Bavarian Nordic A/S Biocartis Group N.V. Forbion...
BioCentury | Jan 12, 2019
Finance

JPM jump-starts 2019

...NASDAQ:UROV) 20% $8.29 Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) 20% $21.08 Seattle Genetics Inc. (NASDAQ:SGEN) 20% $71.41 Biocartis Group N.V....
BioCentury | Dec 21, 2018
Financial News

New Rhein raises $47.7M towards debut fund

...partners Subhanu Saxena and Ivan Gergel, who is also CMO. Parekh previously was CEO of Biocartis Group N.V....
BioCentury | Dec 20, 2018
Financial News

New Rhein raises $47.7M towards debut fund

...partners Subhanu Saxena and Ivan Gergel, who is also CMO. Parekh previously was CEO of Biocartis Group N.V....
BioCentury | Nov 17, 2018
Emerging Company Profile

Sepset’s sepsis signature

...The company signed a deal with Biocartis Group N.V. in January to transfer its sepsis assay to Biocartis’...
BioCentury | May 11, 2018
Company News

Merck, J&J vaccines ready for Ebola outbreak

...glycoprotein and MVA-BN Filo is a modified vaccinia Ankara (MVA) multivalent vaccine. J&J and partner Biocartis Group N.V....
...uses the Biocartis Idylla real-time, reverse transcription-PCR system to detect the virus within 100 minutes. Biocartis...
BioCentury | May 9, 2018
Politics & Policy

Merck, J&J vaccines ready for Ebola outbreak

...glycoprotein and MVA-BN Filo is a modified vaccinia Ankara (MVA) multivalent vaccine. J&J and partner Biocartis Group N.V....
...uses the Biocartis Idylla real-time, reverse transcription-PCR system to detect the virus within 100 minutes. Biocartis...
BioCentury | Feb 22, 2018
Finance

Belgian Insights

...Edwin Moses, Ph.D., CEO, Ablynx N.V. Rudi Pauwels, Ph.D., Founder and Chairman of Strategy Committee, Biocartis Group N.V....
BioCentury | Dec 1, 2017
Financial News

Biocartis raises EUR80M in private placement

...On Nov. 28, diagnostic company Biocartis Group N.V. (Euronext:BCART) raised €80 million ($94.4 million) through the sale of...
...for infectious diseases and oncology based on its Idylla platform. Biocartis Group N.V. (Euronext:BCART), Mechelen, Belgium Elizabeth S. Eaton Biocartis Group N.V....
BioCentury | Nov 29, 2017
Financial News

Biocartis raises €80M in private placement

...Diagnostic company Biocartis Group N.V. (Euronext:BCART) raised €80 million ($94.4 million) through the sale of 6.4 million new...
...menu of diagnostic tests for infectious diseases and oncology based on its Idylla platform. Elizabeth S. Eaton Idylla Biocartis Group N.V....
Items per page:
1 - 10 of 80